AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Defense department awards grant for vaccine development.(Brief Article)

Vaccine Weekly

| March 13, 2002 | COPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2002 MAR 13 - (NewsRx.com & NewsRx.net) -- Plexus Vaccine, Inc., has won a competitive Department of Defense grant. The award provides R&D funding that enables Plexus Vaccine to acquire proof of concept for vaccine development for the biowarfare target, Yersinia pestis, and associated platform technology.

Yersinia pestis is the bacterium that causes the plague.

The award was administered by the Center for the Commercialization of Advanced Technologies .

Plexus Vaccine also will receive services, including market studies and business development support, to help the company ...

Related articles from newspapers, magazines, journals, and more
Plexus Vaccine Inc Selected to Receive Department of Defense-Funded Competitive...
Press release article from: PR Newswire February 8, 2002 700+ words
SAN DIEGO -- Plexus Vaccine Inc, a San Diego biotechnology...funding that enables Plexus Vaccine to acquire proof of concept for vaccine development for the biowarfare target...technology. In addition, Plexus Vaccine will receive services...
Plexus Vaccine Acquires Exclusive Position for Demographically Targeted T-cell...
Press release article from: PR Newswire June 19, 2002 700+ words
...DIEGO and COPENHAGEN, Denmark -- Plexus Vaccine Inc, a San Diego based biotechnology...Valley centered around Copenhagen. Plexus Vaccine, formed in 2001 and based in San Diego...For additional information about Plexus Vaccine, please visit the Company's web...
Plexus Vaccine Inc Appoints Scientific Advisory Board Chaired by Roger Brent Of...
Press release article from: PR Newswire November 1, 2001 700+ words
...CEO of Plexus Vaccine. "Creating...approach to vaccine development will require...Center for Vaccine Development, Univ...Clinical Vaccine Development -- Dr...Enteric Disease Plexus Vaccine Inc incorporates...
Plexus Vaccine, Inc., Appoints Scientific Advisory Board.(Brief Article)
Newspaper article from: Vaccine Weekly November 21, 2001 700+ words
...amp; NewsRx.net) -- Plexus Vaccine, Inc., San Diego...president and CEO of Plexus Vaccine. The Plexus Vaccine Scientific Advisory Board...Myron Levine, Center for Vaccine Development, University of Maryland...
Plexus Vaccine Inc and GlaxoSmithKline Biologicals Sign Structure-Based...
Press release article from: PR Newswire July 22, 2002 700+ words
SAN DIEGO -- Plexus Vaccine Inc announces that it has signed...funded research collaboration, Plexus Vaccine will design chimeric miniproteins...down-stream product rights. "Plexus Vaccine is establishing its leadership...
Plexus Vaccine Inc Forges Licensing Agreement With Molsoft LLC.
Press release article from: PR Newswire September 11, 2001 700+ words
...DIEGO, Sept. 11 /PRNewswire/ -- Plexus Vaccine Inc, a San Diego biotechnology company...s molecular modeling software and Plexus Vaccine's structure-based vaccine design...Dr. Abagyan shall also join the Plexus Vaccine Board of Directors and Scientific Advisory...
Plexus Vaccine Licenses Molsoft To Develop Proprietary Virtual Epitope...
Newspaper article from: TB & Outbreaks Week October 16, 2001 700+ words
...NewsRx.com & NewsRx.net) -- Plexus Vaccine Inc. and Molsoft LLC have entered...s molecular modeling software and Plexus Vaccine's structure-based vaccine design...MolSoft, Dr. Abagyan will join the Plexus Vaccine board of directors and scientific advisory...
Plexus Vaccine, GSK Biologicals ink research agreement.(Brief Article)
Newspaper article from: Vaccine Weekly September 25, 2002 700+ words
...NewsRx.com & NewsRx.net) -- Plexus Vaccine, Inc., has signed a technology development...the funded research collaboration, Plexus Vaccine will design chimeric miniproteins that...certain downstream product rights. "Plexus Vaccine is establishing its leadership position...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA